HUE032461T2 - Hidroxi-alifás szubsztituált fenil-aminoalkil-éter származékok - Google Patents

Hidroxi-alifás szubsztituált fenil-aminoalkil-éter származékok Download PDF

Info

Publication number
HUE032461T2
HUE032461T2 HUE13811569A HUE13811569A HUE032461T2 HU E032461 T2 HUE032461 T2 HU E032461T2 HU E13811569 A HUE13811569 A HU E13811569A HU E13811569 A HUE13811569 A HU E13811569A HU E032461 T2 HUE032461 T2 HU E032461T2
Authority
HU
Hungary
Prior art keywords
ahol ahol
phenyl
phenylpropoxy
methylamino
mmol
Prior art date
Application number
HUE13811569A
Other languages
English (en)
Inventor
Josep R Prous
Neus Serradell
Ramon Flores
Noemi Garcia-Delgado
Banus Marcel­Li Carbo
Original Assignee
Prous Inst For Biomedical Res S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prous Inst For Biomedical Res S A filed Critical Prous Inst For Biomedical Res S A
Publication of HUE032461T2 publication Critical patent/HUE032461T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/267—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/18—Acyclic radicals, substituted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Hydrogenated Pyridines (AREA)

Claims (2)

  1. tgéBy Ml} képbtü vegyük!
    ameivbeír, kk'és R5 jekmése hlörogénmom; ':'^hi!J#íenté-se A-ORs csoport; amelyben A rdenrése CrM Atl^IÉIItértékü K* íckoíváe « IRA s kerék bél alle esoporthal válaszom li, v kV aki vs V tags íV<RV monoctklnsos keteroartl-useport, «mely a gyűrűbe« tartalmas I vagy 2 heteroaîomot s köveik«·· zökhö! álló csoportból egymásról föggeikmül választva; R O és S; isvsgy;;: >ú K' sOenvso H, R* t elemese λ k'‘xerkezoUvó &amp;ilo e^eporrbol \Visított II e» V-Rk alkd, ás R' jeiemese ΙΊ es mvtÖ közül választott; b) R' va R6 együtt egy kovetker/íkbŐI álló esoportbO valasztoó csoportot képemrek: -O-v'H -OH;- os -V Húí W'H; V U -; as A vkuíese ;-\ nso· er Ryjekmésc 0; és fO és Rk együtt -íOhR-CO- csoponot kepe írek: R* jelemése H. R” jelentése adott esetben egy vagy több balogén «ís^ttnáísstisfes^tmáitfenífeeopQrtp n jelentés« Ο, I és 2 kö/ül váktxaíou égés;··- szmo; m jekmése 2 és 4 közül választott egész szám: azzal a megkötéssel hojD ha R4 és R4 jelentése egyaránt H, akkor R6 és R* együtt ·<ΟΗ.·ΐ.·..·ΓΟ· eso-ixntr.ü képezitek; vagy valamely gyógyvzerészeliieg elfogadható sója vagy a/lereobonrero
  2. 2. Az I rgésn pont s/errmul) kepleto xezxuk'k amelyben R' îvlentese VOIT csoport; «mobberí A jOentese erben hatèrk-kà export e 10 jelembe hOrogem atom; R* jekmése léről exoporr R4 és 10 jelentése h idmgénatom; R' jelentése rxselil csoport; és ο értéke I ; vagy valamely gyàgÿssyîîls^îîipsg ell&amp;ggfhsrô «s§4 «^ ρΐ^ϊ^οΐκοωίίϊ«, %.Ä% % vagy 2. IgénypgÉofe Íjémié^Ér Cil töd&amp;di wgyüls|.: ψχφ$ % :$Éfô evepotitïld väfeiitoit: ‘ i -12-f4^2-hUkoxieül>fç»o>{ * 2-j4”|3K^>öt8l&amp;miiiö|-l '#nslpreppgi]&amp;ü^|it|nöI-'hids:o$forid; * ί /ί>-2--Í4-Í J--Ê^ïS;îîiaïïii^<>)--1 '-î^«ll|^î^i>xi]^3Til]^i^sôl'ÎÎÎ^ri>kloyisi; * pf - 244 4 Inô):-·! - f«nl l'propox ijfénif |Mantd4ï idÂte 1¾ * ' [ » X tsaov t\ ipr^í.' M'Un*s Í vV\ h ηνη Ό, ·♦ 2gníc4lan0íK>s4'-le;0!propvXÍÍfc0ÍyetsHol'íeríibav--aö;: * Z-J4-134ffiptûatMh»jKf '.fsmlpävpox i * ^[4-|J»(m^iami«o|l.ixfemipropo)iiJlesniletaïïoKvalpmessv-ad; :*;Z:44'p«(mMÎsmôïô^f*fénHpr<}pi>\ilfônIiIet&amp;8»WR)*Ups>ns»v-#;' » MM* •amino- ! -fs«I|^x>|>oxi)fe«M]etm'#i*H)dmk Jwid; - (4}-2 4443-(maiílsmMí>>* i a;dofën-2'il|popoxilfenil]iîaïïô!; i» 4>-{-*'’(3-{meîiîâmmô)-:l«.f€»Hj»'s>poxtj^Rii|b«té»*.l-^>5»bidrôklorsd| *HHH metjiaromov i v^Hjipr^poNiJfcmJlpropto' Í ~oI»h}<|rokh>rKk » i4434meul&amp;itjin<^|4f^5j||pfopoxîjfeBU'|raeian<>^h5drokk>i-^ :» 2-t4^morf0fc-24Im^*i>fé»U']ë&amp;»oi?îîi&amp;!okIwidj ..« 244-(3-dJ05'^?I^itel4fe»Upropoxi>^RilI«l3*ncl; * 644-3 -meulammo-1-îimifpfOjx«iûf«mil]he*aft-MI; * {5)244-{3 -s0Mils040öíl4iófl»-2viípröpöxsJfeöí!|®ta?5öi; * ' g^u)î'<'Pd'0 2 4kn iptMe^'bv'sdkiv *e' ·, 2444H‘C3^4t>^<4~nuoffert}t}^peÄ^4'l}«i«tei|fp«iQsfe»öi> 4. (jνόgy sstt éatteii kdsdônén y. amok Pmsbga^eiy 1-3. sgsnypotdöl bârspplyiybeH deiplâilv^d-5 é_s <-.gy vagy több gvógysv’erés.íxuleg Ägädisdd hördoadaeyagit g, M t45, történd alkalmazásra·; .g ,^æ ;j4L igéHypöiítök: èàtmeljdk#©®·· φΜΜ vegydfd sdsgrendsstetl feeiepegsk feestddsében .K.-Sagy kognitiv deficittel tárcáid tbjíödéss, yBÂédésI ec/vsgy mentális zavarok kezdésében történd âikaintamsm. y Vegyidet « 6. igénypontban defmidit dkaimaxásra, ahol ;u kkgrendczen b^gségek eVvngy CejlÖ-viselkedési ésévagv Mentális áftök ttmolésí zavarokkal vagy memériaaavarokkai iámtldác ^ Vegyük:; a 6. igénypontban ddloiàM alkalmazásra. itbrds kppliy dëlMifd timuió fejlődési rend·' bligplpëg a következők bői siló esopmtbél választott: Dowrr-szmdróíoa., ArtgelrtsatS'-szindröma, Rett-iszmdzőtna. autKxt&amp;us «avarok. törékeny SsdbiröÄ * wK\ w í> ' vets\ vmKs" 'ι'Π* dî >dk ns**»*;'V» v\\ λ sogiiu > deAedtei vm^m \ dm. »im és-vagy meomfes zavar a kővetkezőkből áHö csoportból választóik depresszió, bipoláris zavar, skizofrénia, agyi demenuak, poszt! tournas stress z&amp;varok. Piek-betegség és .Avas zavarok ife Vegyidet a 6. igénypontban definiált alkalmazásra. ahoi az idegrendszeri betegségek a következőkből álló csoportból válasszon kognitív zavarokkal társuló neurodegene?aíiv zavarok: Airheinwr· kör, Paíktrsaos's-kóí, .Btuniítgt&amp;o-kős< ami öl tói lateralia azk kaőzis, frontofernporáiis domenem o\ i ; ted- á%e| ik \z i 3 panpoi-r.'k beenKikebert defítnak Xi-gyrilet eg> koxmkc/nkivd uife csOivrövi v,ik>sz $0" bgtvgseg kezelésében történő aikslmazfes-s; nc«m|*dÄ· fájdalom, fibmmlulgia,. epilepszia és szlrők. U, Kombináció, amely tartalmaz egy kB, Igénypontok bármelyikében défetiál! végytifeteí és egy má-aik hatóanyagot a kővetkezőkből áho .importból yál&amp;strtsm aceidkolnulszteráz: inhibitorok; NM!>A muwigcnsstik; bLszdamm H? teneglbr' «ntaKomsüsk; béta-szekrgtá«· 1 iftACEI.? inhibitorok; aptfe iaroiloidogéis szerek; >-UT- receptor antagonistak; 5-H Γ. receptor ta-.omstáfc; MA OB irddbifetök; *ΊΛΒΑ{Α4 receptor modulátorok: tmtszkarm M< receptor agonfesták: és gannnnoszekfctdz felnőnötök, jl,,Affgénypüat szerinti kombináció, amelyben az aysiilksdnï|yt|^||lbbibitsg zti: vlö aratóit: ravaszt fernfe, doncpeziL gakmtmrna ëa tmmnzns Λ; az NMDA antagonist** η kő vétkeiről; közül választott: immuniin és but-pbdio; a hia/umln t iá racxpíor antagonists a kiőétkezők kezűi vxhtszrott: pnolizmu, SARd 10894. Atd'-éSk, S-tto»? és ΛΖΙ>»52Π; a bettoszekretx-.a I íBaCEH tfeubtlot a vese iksz ok vous xulu,víoU * .a vs A ο', Vil1 Ok l ö -,i88o'k'. 1, E éoüö <... kik-fe-M, ,u ,í i Oí gő î * Ο * I iv'sWOs \ üi M ,í » p }l<k<!tV* 'g» üt *. i L "'> >« AAD"2004v a?. 5-HTb receptor antagumvta a következük közöl '.shtszfeit: Ltw\E-5kilk, AVN'*32J% kd<kk'lsogtt xiSK AMz ' ez Ni II ' receptor ago-msr.x s Oxwkeznk közéi xdaaziott ki 'bz.oiüé és BíMU-l: a MA*OB inhibitor a kö\oikezek közűi s.'Jasztott: azagiiisi, iadoszrlgíl es RGoO??: a (i 8H \,,'\z receptor Oe du^k'n η \bvcikczok kóz kt, ^hv ok' - Ί'» Ce Rt's 'oo.k t χη^Λζίϊη M rçesptor apsíxkta a::klvetfeezôk kdzüi választott: szahk»>mdin és NíCD- áMpés n easxrma^zekretaz in*, bibiiot a kővetkezők közit! választott, piaitól
HUE13811569A 2012-12-21 2013-12-20 Hidroxi-alifás szubsztituált fenil-aminoalkil-éter származékok HUE032461T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12382527.5A EP2745876A1 (en) 2012-12-21 2012-12-21 Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives

Publications (1)

Publication Number Publication Date
HUE032461T2 true HUE032461T2 (hu) 2017-09-28

Family

ID=47559245

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE13811569A HUE032461T2 (hu) 2012-12-21 2013-12-20 Hidroxi-alifás szubsztituált fenil-aminoalkil-éter származékok

Country Status (11)

Country Link
US (2) US9624158B2 (hu)
EP (2) EP2745876A1 (hu)
JP (1) JP6302929B2 (hu)
AU (1) AU2013366502B2 (hu)
CA (1) CA2895592C (hu)
DK (1) DK2945702T3 (hu)
ES (1) ES2621960T3 (hu)
HR (1) HRP20170539T1 (hu)
HU (1) HUE032461T2 (hu)
PT (1) PT2945702T (hu)
WO (1) WO2014096377A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
SG11201601306QA (en) * 2013-09-09 2016-03-30 Sanofi Sa An h3 receptor antagonist combined with a cholinesterase inhibitor for use in the treatment of alzheimer's disease
CN106349211B (zh) * 2016-08-26 2020-10-16 江苏恩华药业股份有限公司 2-甲基-3-芳氧基-3-杂芳基丙胺类化合物及应用
KR101864085B1 (ko) * 2017-09-22 2018-06-01 동아대학교 산학협력단 발프로산 유도체, 이의 제조방법 및 이를 포함하는 항경련제
US11111220B2 (en) 2017-10-16 2021-09-07 Esteve Pharmaceuticals, S.A. Propanamine derivatives for treating pain and pain related conditions
TW202014191A (zh) 2018-04-27 2020-04-16 日商鹽野義製藥股份有限公司 具有選擇性ｂａｃｅ１抑制活性的四氫哌喃并衍生物
EP3989957A1 (en) * 2019-06-28 2022-05-04 University of Copenhagen Treatment of cns disorders with sleep disturbances

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002254114A1 (en) * 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
JP4342952B2 (ja) * 2002-04-03 2009-10-14 プレバ、バイオテック、ソシエダッド、アノニマ 神経変性疾患の防御のための天然フェノール系産物およびその誘導体
GB0409744D0 (en) 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
CA2564994A1 (en) * 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
SE0401936L (sv) 2004-07-27 2005-08-16 Jan Norrman Kopplingsstycke innefattande en ledare med flertal trådar vilka är fördelade kring en deformerbar kropps ytteromkrets
GB0505509D0 (en) * 2005-03-17 2005-04-27 Ic Innovations Ltd Compounds
ES2374964T3 (es) 2006-01-25 2012-02-23 Sanofi Agentes citotóxicos que comprenden nuevos derivados de tomaimicina.
CN100528832C (zh) * 2007-02-08 2009-08-19 刘宏民 左旋盐酸倍他洛尔合成工艺
US20120004310A1 (en) * 2010-05-28 2012-01-05 Longo Frank M Non-peptide bdnf neurotrophin mimetics
EP2664616A1 (en) * 2012-05-15 2013-11-20 Vivalis Hydantoin and thiohydantoin derivatives as antiviral drugs

Also Published As

Publication number Publication date
DK2945702T3 (en) 2017-04-18
ES2621960T3 (es) 2017-07-05
US9624158B2 (en) 2017-04-18
WO2014096377A1 (en) 2014-06-26
EP2745876A1 (en) 2014-06-25
US20170239197A1 (en) 2017-08-24
JP2016504992A (ja) 2016-02-18
HRP20170539T1 (hr) 2017-06-16
AU2013366502A1 (en) 2015-07-09
US9980928B2 (en) 2018-05-29
CA2895592A1 (en) 2014-06-26
JP6302929B2 (ja) 2018-03-28
EP2945702B1 (en) 2017-01-11
EP2945702A1 (en) 2015-11-25
AU2013366502B2 (en) 2017-12-14
PT2945702T (pt) 2017-04-20
US20150344408A1 (en) 2015-12-03
CA2895592C (en) 2019-10-29

Similar Documents

Publication Publication Date Title
US9980928B2 (en) Hydroxy aliphatic substituted phenyl aminoalkyl ether derivatives
Lindberg et al. Inhibitors of neuronal monoamine uptake. 2. Selective inhibition of 5-hydroxytryptamine uptake by. alpha.-amino acid esters of phenethyl alcohols
US7501541B2 (en) Malonamides as orexin antagonists
UA81186C2 (en) N-heterocyclylmethyl benzamide derivatives, preparation thereof and use in therapy
Saravanan et al. Anticonvulsant activity of novel 1-(morpholinomethyl)-3-substituted isatin derivatives
ES2734734T3 (es) Compuestos de amida como agonistas del receptor 5-HT4
US11420950B2 (en) Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same
CN110573497A (zh) 组蛋白脱乙酰基酶抑制剂
Böck et al. N‐Substituted Nipecotic Acids as (S)‐SNAP‐5114 Analogues with Modified Lipophilic Domains
US20220220102A1 (en) D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof
Wallach Structure activity relationship (SAR) studies of arylcycloalkylamines as N-methyl-D-aspartate receptor antagonists
JP2007508314A (ja) ピロバレロン類縁体及びそれらの治療的使用
JP2011510022A (ja) Ｎ−及びｏ−置換型の４−［２−（ジフェニルメトキシ）−エチル］−１−［（フェニル）メチル］ピペリジンアナログ、及びそれを用いたｃｎｓ障害を治療する方法
CN107459510B (zh) 异恶唑类化合物及其应用
WO2020145831A1 (en) (2,5-dioxopyrrolidin-l-yl)(phenyl)-acetamide derivatives and their use in the treatment of neurological diseases
BRPI0620035A2 (pt) compostos, medicamento, composição farmacêutica, método para preparar a mesma, e, uso de um composto
EP2185525B1 (fr) Dérivés de pyrazole 3,5-carboxylates, leur préparation et leur application en thérapeutique
JP2009536644A (ja) 中枢神経系活動に用いるシクロプロパン
JP2010511615A (ja) 中枢神経系障害用薬剤としてのピバガビンのジアルキルアミノアルキルエステル
JP4565747B2 (ja) テトラヒドロイソキノリンアルカノール誘導体及びそれを含む薬学的組成物
Shirai et al. Design, structure–activity relationship, and highly efficient asymmetric synthesis of 3-phenyl-4-benzylaminopiperidine derivatives as novel neurokinin-1 receptor antagonists
Estrada Valencia Exploring the N-Benzylpiperidine and N, N-Dibenzyl (N-Methyl) amine fragments as privileged structures in the search of new multitarget directed drugs for Alzheimer's disease
Valencia Exploring the N-Benzylpiperidine and N. N-Dibenzyl (N-Methyl) amine fragments as privileged structures in the search of new multitarget directed drugs for Alzheimer's disease
FR2874215A1 (fr) Derives de cyclopropylmethanones, leur preparation et leur utilisation en therapeutique